This study protocol outlines a prospective observational study to compare the early pharmacokinetics and pharmacodynamics of a ticagrelor loading dose between STEMI and NSTEMI patients undergoing invasive management.
No takes yet. Share an insight, caveat, or question.
No change to ticagrelor use by AMI type warranted; leaves open whether platelet reactivity differences affect outcomes.
Adamski et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: